5 reasons to prefer the MOAB-2 antibody in Alzheimer ‘s Disease research

The new pan-specific MOAB-2 is a high-titer monoclonal antibody to Aβ residues 1-4. Here are 5 main reasons that will make you choose it for your research on Alzheimer’s Disease research programs!

#1 – MOAB-2 ensures unparalleled staining quality and clear staining

MOAB-2 provides stronger reactivity and greater sensitivity than any other Aβ monoclonals previously available for research.

#2 – MOAB-2 discriminates between APP and true intraneuronal Aβ in all its forms

Aβ accumulates extracellularly as the disease progresses, making MOAB-2 the ideal reagent for studying both intraneuronal Aβ at early stages and extracellular Aβ at later stages seamlessly.

You’ll get accurate data.

#3 – MOAB-2 does not cross react with APP or APP C-terminal fragments

Unlike other monoclonals such as 6E10 and 4G8, MOAB-2 does not cross react with APP or APP C-terminal fragments, which allows you better isolation and localization of Aβ protein from APP.

MOAB-2 in immunohistochemical detection of Aβ and APP in coronal sections of the frontal cortex of 1-month old 5xFAD mice.

Immunohistochemical detection of Aβ and APP in coronal sections of the frontal cortex of 1-month old 5xFAD mice. Sections were co-stained with M-1586-100 or APP antibodies (N-terminus and C-terminus). MOAB-2 staining was punctate and did not co-localize with either APP antibodies. Figure courtesy of Youmans et al (2012).

#4 – MOAB-2 detects pathogenic Aβ42 over Aβ40

In dot blots, MOAB-2 recognizes all forms (unaggregated, oligometric, and fibrillar) of Aβ 42 protein and the unaggregated form of AB40. MOAB-2 is selective for the more neurotoxic Aβ42 compared to Aβ40. In titration tests, MOAB-2 demonstrated 25 fold greater sensitivity of detection for the U-, O- and F-Aβ42 forms than for Aβ40.

This will allow you to work on the localization and function of Aβ42.

#5 – MOAB-2 belongs to the “tebu-bio Antibody Trial Program”

A large number of antibody trial sizes are available at tebu-bio. The trial size format of the monoclonal MOAB-2 is a 20-µg vial. It’s an ideal size for research teams keen to validate this monoclonal in their AD and neurobiology studies.

Want to benefit from the “tebu-bio Antibody Trial Program” at affordable prices?

Get your 20-µg MOAB-2 by following this link.

 

 

MOAB-2 Monoclonal in IF

IHC staining of MOAB-2 on 2,4 and 6 month old 5XFAD mouse hippocampal sections showing increasing Aß staining with MOAB-2 (Red); NeuN staining (Green). Photo courtesy of Dr. Mary Jo LaDu and Dr. Leon Tai from the University of Illinois Chicago, Chicago, IL

Trackbacks

  1. […] 5 reasons to prefer the MOAB-2 antibody in Alzheimer‘s Disease research […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: